New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
14:19 EDTCELG, XLRNCelgene, Acceleron announce interim data from beta-thalassemia study
Celgene (CELG) and Acceleron Pharma (XLRN) announced interim data from two studies of candidates from the companiesí joint development program in beta-thalassemia. The data presented at the 19th European Hematology Association, EHA, annual congress show activity for two programs, sotatercept and ACE-536, in patients with both transfusion dependent and non-transfusion dependent beta-thalassemia. There is currently no drug approved to treat beta-thalassemia. Both sotatercept and ACE-536 have been granted orphan drug designation for beta-thalassemia by the FDA.
News For CELG;XLRN From The Last 14 Days
Check below for free stories on CELG;XLRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
09:31 EDTXLRNAcceleron management to meet with JMP Securities
Subscribe for More Information
September 17, 2014
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
14:06 EDTXLRNAcceleron management to meet with Leerink
Subscribe for More Information
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use